FRA
PACB icon

Front Row Advisors’s Pacific Biosciences PACB Stock Holding History

Front Row Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$33K – 973
2021
Q1 		$33K Buy
+1,000
New +$35K 0.02% 318

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Front Row Advisors's PACB Position: Q2 2021 in Review

Front Row Advisors sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 1,000 shares — an estimated $33K sold.

Front Row Advisors first reported a position in PACB in Q1 2021 and held it in 1 quarter. The position peaked at $33K in Q1 2021. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

  • Front Row Advisors reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
  • Front Row Advisors sold 1,000 Pacific Biosciences shares in Q2 2021, an estimated $33K.
  • Front Row Advisors first reported a position in Pacific Biosciences in Q1 2021 and held it in 1 quarter.
  • Front Row Advisors's Pacific Biosciences position peaked at $33K in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on Front Row Advisors's 13F filing for Q2 2021, filed 23 Aug 2021.